ABVC BioPharma, Inc. Share Price & Technical Analysis
ABVC · $1.14 (+1.79%)
Healthcare / Biotechnology
$1.14
+1.79%
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II c…
Price chart
Seasonality
May has 2 positive and 3 negative years (last 5 years shown)
10% return in May, 0% avg return in past 3 year May month.
-53% return in 2026, -13% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -5% | -35% | -23% | 0% | 10% | – | – | – | – | – | – | – | -53% |
| 25 | -17% | 40% | 57% | 0% | 40% | 57% | 4% | 17% | 7% | -7% | -4% | -22% | 173% |
| 24 | 25% | -20% | 8% | -8% | -33% | 0% | 0% | -12% | 0% | 0% | -29% | 0% | -69% |
| 23 | 20% | -10% | -7% | 6% | -6% | -24% | -53% | -70% | -23% | 0% | 30% | -8% | -143% |
| 22 | -26% | -6% | 13% | -11% | -16% | -46% | -38% | 51% | -16% | -25% | -1% | -16% | -138% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Downtrend · Uptrend
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple negative breast cancer; ABV-1504, which has completed Phase II clinical trials for depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-2001, an intraocular irrigation solution; ABV-2002, a corneal Storage Solution; and ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. The company has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$26.64M
P/E ratio
—
52W high
$5.48
52W low
$0.88
Volume
2,54,574
Beta
0.42
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is ABVC BioPharma, Inc. share price today?
- ABVC BioPharma, Inc. (ABVC) last traded around $1.14 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does ABVC have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for ABVC. Download the app for real-time alerts.
- How can I analyze ABVC BioPharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.